Table 2.
Clinicopathological variables in de novo MBC versus distant recurrent MBC, stratified by levels of Mo-MDSCs
| Clinicopathological variable | De novo MBCa | Distant recurrent MBCb | P valuec | ||
|---|---|---|---|---|---|
| Normal levels n = 2 (%) | High levels n = 10 (%) | Normal levels n = 26 (%) | High levels n = 16 (%) | ||
| Age (years) | |||||
| < 65 | 1 (50) | 7 (70) | 12 (46) | 7 (44) | 1.0 |
| ≥ 65 | 1 (50) | 3 (30) | 14 (54) | 9 (56) | |
| Baselined ECOGe | |||||
| 0 | 1 (50) | 6 (60) | 19 (73) | 9 (60) | 0.70 |
| 1 | 0 (0) | 0 (0) | 3 (12) | 3 (20) | |
| 2 | 1 (50) | 4 (40) | 4 (15) | 3 (20) | |
| Unknown | 0 | 0 | 0 | 1 | |
| Tumor type | |||||
| Ductal | 2 (100) | 8 (89) | 20 (80) | 10 (63) | 0.31 |
| Lobular | 0 (0) | 1 (11) | 3 (12) | 5 (31) | |
| Other | 0 (0) | 0 (0) | 2 (8) | 1 (6) | |
| Unknown | 0 | 1 | 1 | 0 | |
| PT NHG | |||||
| I | – | – | 3 (13) | 1 (8) | 0.88 |
| II | – | – | 14 (58) | 9 (69) | |
| III | – | – | 7 (29) | 3 (23) | |
| Unknown | 4 | 13 | |||
| PT tumor size | |||||
| T1 | 0 (0) | 0 (0) | 13 (50) | 7 (46) | 0.30 |
| T2 | 0 (0) | 2 (29) | 8 (31) | 4 (27) | |
| T3 | 0 (0) | 1 (14) | 2 (8) | 4 (27) | |
| T4 | 0 (0) | 4 (57) | 3 (11) | 0 (0) | |
| Unknown | 2 | 3 | 0 | 1 | |
| PT node status | |||||
| Negative | 0 (0) | 0 (0) | 11 (42) | 4 (25) | 0.33 |
| Positive | 0 (0) | 4 (100) | 15 (58) | 12 (75) | |
| Unknown | 2 | 6 | 0 | 0 | |
| PT hormone receptor status | |||||
| ER-negative | 0 (0) | 4 (44) | 3 (12) | 5 (38) | 0.09 |
| ER-positive | 1 (100) | 5 (56) | 22 (88) | 8 (62) | |
| Unknown | 1 | 1 | 1 | 3 | |
| PR-negative | 0 (0) | 4 (44) | 8 (32) | 7 (58) | 0.16 |
| PR-positive | 1 (100) | 5 (56) | 17 (68) | 5 (42) | |
| Unknown | 1 | 1 | 1 | 4 | |
| PT HER2 status | |||||
| HER2-negative | 0 (0) | 6 (67) | 18 (90) | 8 (89) | 1.0 |
| HER2-positive | 1 (100) | 3 (33) | 2 (10) | 1 (11) | |
| Unknown | 1 | 1 | 6 | 7 | |
| MET hormone receptor status | |||||
| ER-negative | 1 (50) | 2 (33) | 1 (4) | 3 (19) | 0.29 |
| ER-positive | 1 (50) | 4 (67) | 22 (96) | 13 (81) | |
| Unknown | 0 | 4 | 3 | 0 | |
| PR-negative | 1 (50) | 3 (50) | 12 (55) | 11 (69) | 0.51 |
| PR-positive | 1 (50) | 3 (50) | 10 (45) | 5 (31) | |
| Unknown | 0 | 4 | 4 | 0 | |
| MET HER2 status | |||||
| HER2-negative | 1 (50) | 6 (100) | 18 (86) | 14 (93) | 0.63 |
| HER2-positive | 1 (50) | 0 (0) | 3 (14) | 1 (7) | |
| Unknown | 0 | 4 | 5 | 1 | |
| Metastatic sites, n | |||||
| < 3 | 1 (50) | 4 (40) | 19 (73) | 9 (56) | 0.32 |
| ≥ 3 | 1 (50) | 6 (60) | 7 (27) | 7 (44) | |
| Metastatic sites, localization | |||||
| Lymph node | |||||
| Negative | 0 (0) | 2 (20) | 18 (69) | 11 (69) | 1 |
| Positive | 2 (100) | 8 (80) | 8 (31) | 5 (31) | |
| Lung | |||||
| Negative | 1 (50) | 7 (70) | 15 (58) | 10 (62) | 1 |
| Positive | 1 (50) | 3 (30) | 11 (42) | 6 (38) | |
| Liver | |||||
| Negative | 1 (50) | 6 (60) | 22 (85) | 9 (56) | 0.07 |
| Positive | 1 (50) | 4 (40) | 4 (15) | 7 (44) | |
| Bone | |||||
| Negative | 1 (50) | 0 (0) | 9 (35) | 2 (13) | 0.16 |
| Positive | 1 (50) | 10 (100) | 17 (65) | 14 (87) | |
| Visceralf | |||||
| Non-visceral | 0 (0) | 4 (40) | 11 (42) | 5 (31) | 0.53 |
| Visceral | 2 (100) | 6 (60) | 15 (58) | 11 (69) | |
| Bone only | |||||
| Not bone-only | 2 (100) | 9 (90) | 20 (77) | 12 (75) | 1 |
| Bone-only | 0 (0) | 1 (10) | 6 (23) | 4 (25) | |
| Progression at 3 months’ evaluation | |||||
| Non-progression | 1 (100) | 7 (88) | 22 (92) | 9 (64) | 0.08 |
| Progression | 0 (0) | 1 (12) | 2 (8) | 5 (36) | |
| Unknown | 1 | 2 | 2 | 2 | |
| CTC at baselined | |||||
| < 5 | 1 (100) | 4 (40) | 15 (58) | 5 (31) | 0.12 |
| ≥ 5 | 0 (0) | 6 (60) | 11 (42) | 11 (69) | |
| Unknown | 1 | 0 | 0 | 0 | |
Number of patients and percentage (%) distribution of patients indicated for each variable
MBC metastatic breast cancer, Mo-MDSCs monocytic myeloid-derived suppressor cells, ECOG Eastern Cooperative Oncology Group, PT primary tumor, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, MET metastasis, CTC circulating tumor cells
aDe novo MBC defined as MBC at initial breast cancer diagnosis, n too small for statistical analysis and no P values are listed
bDistant recurrent MBC defined as MBC diagnosis after > 0 years after primary diagnosis
cStatistics by Fisher’s exact test. Significance level defined as P < 0.05 (bold)
dBaseline defined as a time point before starting first line systemic MBC treatment
eECOG denotes the performance status used in clinical practice in Sweden
fVisceral metastasis is defined as lung, liver, brain, peritoneal, and/or pleural involvement